Publication Cover
AIDS Care
Psychological and Socio-medical Aspects of AIDS/HIV
Volume 27, 2015 - Issue 1
284
Views
24
CrossRef citations to date
0
Altmetric
Articles

Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation

, , , , , , , , , , & show all
Pages 86-92 | Received 27 Feb 2014, Accepted 26 Aug 2014, Published online: 29 Sep 2014
 

Abstract

Antiretroviral therapy (ART) became more widely available in the Russian Federation in 2006 when the Global Fund made a contribution to purchase ART with a mandate to increase numbers of patients receiving it. Funds were distributed to AIDS Centers and selected hospitals, and numbers quickly increased. Though ART is highly effective for adherent patients, dropout has been a problem; thus understanding characteristics of patients who remain on ART vs. those who leave treatment may provide information to facilitate engagement. We retrospectively assessed depression, hopelessness, substance use, viral load, and CD4+ counts of 120 patients who dropped out of ART for ≥12 months (Lost-to-Care, LTCs) and 120 who continued for ≥12 months (Engaged-in-Care, EICs). As expected, LTCs had higher viral loads and depression, lower CD4+ counts, more alcohol, heroin, and injection drug use in the past 30 days. A binary logistic regression with Center for Epidemiologic Studies Depression score, Beck Hopelessness score, whether drugs/alcohol had ever prevented them from taking ART, and past 30 days' alcohol use [χ2(4) = 64.27, p = .0.000] correctly classified 74.5% of participants as LTC or EIC, suggesting that integrated treatment for substance use, psychiatric, and HIV could reduce dropout and improve outcomes.

Acknowledgments

We would like to thank the participants, Botkin Hospital, and Leningrad Regional AIDS Center.

Funding

This study was supported by funding from the Office of the U.S. Global AIDS Coordinator through the PEPFAR program.

Notes

1. LTCs did not receive HIV treatment at these facilities.

2. Agonist treatments are legally unavailable in the Russian Federation.

Additional information

Funding

Funding: This study was supported by funding from the Office of the U.S. Global AIDS Coordinator through the PEPFAR program.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.